Send to

Choose Destination
Int J Radiat Oncol Biol Phys. 2003 Mar 15;55(4):907-13.

Posttherapy surveillance monitoring of cervical cancer by FDG-PET.

Author information

Department of Radiation Oncology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA.



To evaluate the effect of irradiation and chemotherapy for carcinoma of the uterine cervix on posttreatment tumor uptake of the glucose analog (18)F-fluorodeoxyglucose (FDG) imaged by positron emission tomography (PET) and to assess the utility of FDG-PET for surveillance monitoring.


This was a retrospective review of 76 patients with a new diagnosis of carcinoma of the uterine cervix who underwent pre- and posttreatment whole-body FDG-PET. Posttreatment FDG-PET was performed 2.4-10.4 months (median 4.2) after irradiation completion.


After treatment, persistent abnormal FDG uptake in the cervix was found in 18% (14 of 76), in the pelvic lymph nodes in 16% (9 of 55), in the paraaortic lymph nodes in 45% (5 of 11), and in the supraclavicular lymph nodes in 75% (3 of 4). Eleven patients developed new sites of increased FDG uptake. In relation to the findings on posttreatment PET, the 2-year progression-free survival rate was 86% for patients with no abnormal FDG uptake at any site and 40% for those with persistent abnormal uptake; there were no survivors at 2 years among patients who developed new sites of abnormal FDG uptake (p <0.0001). A multivariate analysis of prognostic factors demonstrated that any posttreatment abnormal FDG uptake (persistent or new) was the most significant prognostic factor (p <0.0001) for death from cervical carcinoma.


FDG-PET is a valuable tool to evaluate the response of primary cervical carcinoma and lymph node metastasis to treatment and for the surveillance of patients after initial therapy.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center